On December, 13. Investors wait KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) to report its quarterly earnings, according to Zacks. Last year’s EPS was $-0.5, while now analysts expect change of 2.00 % down from current $-0.51 EPS. Wall Street now sees 8.51 % negative EPS growth despite KalVista Pharmaceuticals, Inc. previous quarter’s EPS of $-0.47. The stock decreased 0.16% or $0.03 during the last trading session, touching $18.97.Currently KalVista Pharmaceuticals, Inc. is uptrending after 81.98% change in last November 9, 2017. KALV has also 29,366 shares volume. The stock outperformed the S&P 500 by 66.36%.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors.The company has $325.90 million market cap. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.Currently it has negative earnings. The Company’s products include KVD001, an intravitreally administered plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein, which is in Phase I clinical trial for treating HAE.
More recent KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) news were published by Seekingalpha.com, Nasdaq.com and Streetinsider.com. The first one has “Premarket analyst action – healthcare” as a title and was published on October 15, 2018. The next is “Report: Exploring Fundamental Drivers Behind Syndax Pharmaceuticals, Arconic, Del Taco Restaurants, Aerohive …” on October 18, 2018. And last was published on October 15, 2018, called “Stifel Starts Kalvista Pharmaceuticals Inc (KALV) at Buy”.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.